Elanco logo with Financial News caption
21 February 2023

Elanco Animal Health Reports Fourth Quarter and Full Year 2022 Results


Post by: Colleen Parr Dekker

  • Fourth Quarter 2022 Financial Results:
    • Revenue of $988 million
    • Reported Net Loss of $54 million, Adjusted Net Income of $95 million
    • Adjusted EBITDA of $174 million or 17.6% of Revenue
    • Reported EPS of $(0.11), Adjusted EPS of $0.19
    • Net leverage ratio of 5.4x Adjusted EBITDA
  • Full Year 2023 Guidance:
    • Revenue of $4,280 to $4,400 million
    • Reported Net Loss of $(157) to $(109) million, Adjusted EBITDA of $920 to $1,000 million
    • Reported EPS of $(0.32) to $(0.22), Adjusted EPS of $0.74 to $0.83
  • Initiated submission for JAK Inhibitor to the U.S. FDA with path to approval by first half of 2024; Received U.S. FDA approval of Bexacat, the first SGLT-2 inhibitor for feline diabetes, and U.S. EPA approval for the re-launch of two OTC parasiticides, Advantage for cats and K9 Advantix for dogs –new offerings in value segments.
  • Updating expectations for U.S. approval and launch of Bovaer, a methane-reducing feed ingredient for cattle with blockbuster potential, by the first half of 2024.

GREENFIELD, IN (February 21, 2023) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2022, and provided initial guidance both for the first half and full year 2023.

To view full Press Release, click here.

Investor Contact

Kathryn Grissom



Media Contact

Colleen Parr Dekker




    Connect with Elanco

    Country selector

    Elanco's Healthy Purpose, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2022 Elanco or its affiliates.